MedTrace Logo

CD45BE-HSPC + CART-45 Cells

NCT07451054 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-05-14

No results posted yet for this study

Summary

This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.

Conditions

  • B-Cell Non-Hodgkin Lymphoma (NHL)
  • Richter's Transformation
  • T-Cell Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma

Interventions

BIOLOGICAL

CART-45 cells

Autologous base edited anti-CD45 CAR T cells

BIOLOGICAL

CD45BE-HSPC

CD45 base edited hematopoietic stem and progenitor cells

Sponsors & Collaborators

Principal Investigators

  • Noelle Frey, MD · University of Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2051-07-31
Completion
2051-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07451054 on ClinicalTrials.gov